Having trouble accessing articles? Reset your cache.

Lynparza shows PFS benefit of 3.6 months in pancreatic cancer

AstraZeneca’s Lynparza olaparib has hit the minimum three-month benefit that oncologists were hoping to see in pancreatic cancer. Data presented Sunday at ASCO position the PARP inhibitor to become the first targeted agent to

Read the full 347 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers